¹⁷⁷Lu-PSMA-ALB-56 is a radiolabeled PSMA analogue developed for prostate cancer therapy by the Center for Radiopharmaceutical Sciences ETH-PSI-USZ (Zurich Switzerland) and the Paul Scherrer Institute in Villigen (Switzerland). This molecule is based on a new PSMA Ligand modified with an albumin-binding moiety in order to optimize the tissue distribution profile.
A clinical trial (Phase I) was initiated in April 2021.

Target/Mechanism: PSMA

Carrier/Ligand: PSMA-ALB-56

Radiation Type: beta electrons (β^–)